These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 25282036)

  • 1. A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry.
    Santacana M; Maiques O; Valls J; Gatius S; Abó AI; López-García MÁ; Mota A; Reventós J; Moreno-Bueno G; Palacios J; Bartosch C; Dolcet X; Matias-Guiu X
    Hum Pathol; 2014 Dec; 45(12):2394-403. PubMed ID: 25282036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
    Alvarez T; Miller E; Duska L; Oliva E
    Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
    Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
    Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes.
    Alkushi A; Köbel M; Kalloger SE; Gilks CB
    Int J Gynecol Pathol; 2010 Jul; 29(4):343-50. PubMed ID: 20567148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
    Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
    Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IMP2 expression distinguishes endometrioid from serous endometrial adenocarcinomas.
    Zhang L; Liu Y; Hao S; Woda BA; Lu D
    Am J Surg Pathol; 2011 Jun; 35(6):868-72. PubMed ID: 21566514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
    Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
    Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma.
    Cuevas D; Valls J; Gatius S; Roman-Canal B; Estaran E; Dorca E; Santacana M; Vaquero M; Eritja N; Velasco A; Matias-Guiu X
    Virchows Arch; 2019 May; 474(5):585-598. PubMed ID: 30710169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas.
    Coenegrachts L; Garcia-Dios DA; Depreeuw J; Santacana M; Gatius S; Zikan M; Moerman P; Verbist L; Lambrechts D; Matias-Guiu X; Amant F
    Virchows Arch; 2015 Apr; 466(4):415-22. PubMed ID: 25677978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylation profiles of endometrioid and serous endometrial cancers.
    Seeber LM; Zweemer RP; Marchionni L; Massuger LF; Smit VT; van Baal WM; Verheijen RH; van Diest PJ
    Endocr Relat Cancer; 2010 Sep; 17(3):663-73. PubMed ID: 20488783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-associated macrophages, epidermal growth factor receptor correlated with the triple negative phenotype in endometrial endometrioid adenocarcinoma.
    Jiang XF; Tang QL; Shen XM; Li HG; Chen LH; Wang XY; Luo X; Lin ZQ; Jiang GY
    Pathol Res Pract; 2012 Dec; 208(12):730-5. PubMed ID: 23122929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
    Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
    Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human epidermal growth factor receptor-2 (HER2) expression in FIGO3 high-grade endometrial endometrioid carcinoma: Clinicopathologic characteristics and future directions.
    Abada E; Kim S; Jang H; Kheil M; Singh K; Bandyopadhyay S; Ali-Fehmi R; Quddus MR
    Gynecol Oncol; 2024 Jun; 185():25-32. PubMed ID: 38364692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis.
    McCluggage WG; Connolly LE; McBride HA; Kalloger S; Gilks CB
    Histopathology; 2012 Mar; 60(4):547-53. PubMed ID: 22250726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MMP-2, TIMP-1, E-cadherin, and beta-catenin expression in endometrial serous carcinoma compared with low-grade endometrial endometrioid carcinoma and proliferative endometrium.
    Shaco-Levy R; Sharabi S; Piura B; Sion-Vardy N
    Acta Obstet Gynecol Scand; 2008; 87(8):868-74. PubMed ID: 18607832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of insulin-like growth factor II mrna-binding protein 3 (IMP3) expression with prognostic and morphological factors in endometrial cancer.
    Salum SOR; Candido EB; Domingues MAC; Ojopi EPB; Tonon ÂFS; da Silva-Filho AL
    Rev Bras Ginecol Obstet; 2024; 46():. PubMed ID: 39176196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Immunohistochemistry to Distinguish Grade 3 Endometrioid Carcinoma and Uterine Serous Carcinoma.
    Zaidi A; Gupta P; Gupta N; Rajwanshi A; Rai B; Gainder S
    Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):42-48. PubMed ID: 31815745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma.
    Gilks CB; Oliva E; Soslow RA
    Am J Surg Pathol; 2013 Jun; 37(6):874-81. PubMed ID: 23629444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
    Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
    Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-associated macrophages correlate with progesterone receptor loss in endometrial endometrioid adenocarcinoma.
    Jiang XF; Tang QL; Li HG; Shen XM; Luo X; Wang XY; Lin ZQ
    J Obstet Gynaecol Res; 2013 Apr; 39(4):855-63. PubMed ID: 23106983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.